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1 Recital 9 Directive 91/414 of 15 July 1991 concerning the placing 
of plant protection products on the market (OJ 1991 L 230, p. 1), as 
amended by Regulation (EC) No 396/2005 of the European Parlia-
ment and of the Council of 23 February 2005 (OJ 2005 L 70, p. 1) 
(“Directive 91/414”). The general purpose of Directive 91/414 is to 
harmonise across EU Member States the rules on conditions and 
procedures for the authorization of plant protection products. 
2 Article 3 Directive 91/414.
3 Article 5(1) Directive 91/414. When deciding the insertion of ac-
tive substances in Annex I, the following factors should be taken 
into consideration: (i) an acceptable daily intake (ADI) for man, if 
relevant; (ii) an acceptable operator exposure level, if necessary; 
and (iii) an estimate of its fate and distribution in the environment 
and its impact on non-target species (Article 5(2) Directive 91/414). 
Authorizations in relation to active substances are issued at EU 
level. An active substance is included in Annex I for a period not 
exceeding 10 years, and the inclusion is renewable once or more 
for additional periods not exceeding 10 years (Article 5(5) Direc-
tive 91/414).
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 Products and Provisional Marketing Authorization: 
The ECJ’s Decision in Lovells v. Bayer
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Case C-229/09 Hogan Lovells International LLP v. Bayer CropScience AG
The European Court of Justice (ECJ) rendered a decision regarding supplementary 
protection certificates (SPCs) for plant protection products and provisional marketing 
 authorisation. The ECJ clarified that SPCs for patented plant protection products may 
also be based on provisional marketing authorizations pursuant to Article 8(1) Direc-
tive 91/114 (author’s headnote).
I.  Introduction: Plant protection pro-
ducts, marketing authorization and 
supplementary protection certificates
On 11 November 2010 the European Court of Jus-
tice (ECJ) rendered an interesting decision regard-
ing supplementary protection certificates (SPCs) for 
plant protection products and provisional marketing 
authorisation (Case C-229/09, Hogan Lovells Interna-
tional LLP v. Bayer CropScience AG).
Plant protection products, such as agricultural 
and horticultural pesticides, fungicides and insecti-
cides, are nowadays more and more necessary be-
cause plant yields are often affected by destructive 
organisms, including weeds, pests of plants, viruses, 
bacteria, mycoplasmas and other pathogens. They 
are therefore useful to (i) protect plants against such 
risks, (ii) contribute to the continuing improvement 
in the production of food of good quality and (iii) 
help to ensure security of supplies. However, plant 
protection products may also be detrimental to 
plant production and also entail risks and hazards 
for humans, animals and the environment, particu-
larly where they are marketed without any testing or 
when they are incorrectly used. That is why Direc-
tive 91/414 concerning the placing of plant protection 
products on the market was adopted: its aim is to 
subject these products to marketing authorizations 
with a view to ensuring “a high standard of protec-
tion, which, in particular, must prevent the authoriza-
tion of plant protection products whose risks to health, 
groundwater and the environment and human and 
animal health should take priority over the objective 
of improving plant production”1. Indeed a plant pro-
tection product cannot be marketed and used in the 
EU unless the competent authorities of the Member 
State in question have granted the relevant market-
ing authorization pursuant to Directive 91/4142.
Requirements for obtaining this administrative 
approval are stringent. First of all, the active sub-
stances of the products must be included in a spe-
cific list (Annex I to Directive 91/414). Substances are 
listed in Annex I if in the light of current scientific 
and technical knowledge their residues and use do 
not have any harmful effects on human or animal 
health or on groundwater or exert any unacceptable 
influence on the environment3. Similar requirements 
are provided with reference to final (plant protection) 
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products: they should not be authorized unless it is 
established that inter alia (i) they are sufficiently ef-
fective, (ii) they have no unacceptable effect on plants 
or plant products, (iii) they do not cause unnecessary 
suffering and pain to vertebrates to be controlled, (iv) 
they have no harmful effect on human or animal 
health, directly or indirectly (for example in relation 
to drinking water, food or feed) and (v) they have no 
unacceptable influence on the environment4.
To guarantee the free circulation of plant produc-
tion products, Article 10 Directive 91/414 provides for 
mutual recognition of authorizations granted by EU 
Member States, as long as the plant health, agricul-
tural and environmental conditions are comparable 
in the countries concerned. Yet Article 11 sets forth 
a protective clause allowing countries to provision-
ally restrict or prohibit the use or sale of the plant 
protection product in question on its territory if it 
constitutes a risk to human or animal health or to 
the environment.
Plant protection research needs strong investment. 
In particular, manufacturing plant protection prod-
ucts often requires significant financial and human 
efforts. Patent protection, by offering exclusive ex-
ploitation rights to whoever comes up with new and 
original inventions, is meant to be a solution to stim-
ulate and recoup these investments. Indeed, many 
plant protection products are covered by patents. In 
most countries patents last for 20 years from the time 
the patent application is filed5.
Yet, as we have seen above, the products in ques-
tion must obtain regulatory approval prior to their 
commercialization. And the ordinary approval pro-
cess is usually time-consuming and imposes substan-
tial delays prior to the product coming on the market. 
Thus, where a plant protection product is the subject 
of a patent, such delay de facto reduces the effective 
term of patent protection, making it much less than 
20 years. This clearly makes patent exploitation un-
economic. That is why Regulation 1610/96 created 
supplementary protection certificates (SPCs) for plant 
protection products subject to an administrative au-
thorization procedure6. SPCs extend the life of the 
patent for a certain period of time in order to partly 
set off the above-mentioned loss of the period of pat-
ent protection. The extension aims therefore at avoid-
ing a penalization of the competitiveness of the plant 
protection industry. An analogous system of supple-
mentary protection had already been provided in re-
lation to patented medicinal products, which are also 
subject to administrative authorization procedures7.
According to Article 3(1)(b) Regulation 1610/96, 
SPCs are granted in relation to plant protection prod-
ucts covered by a patent if inter alia a valid authori-
zation to market the product in question has been 
granted pursuant to Article 4 Directive 91/414.
II.  The facts of the case and the referral 
to the ECJ
The case originated from a German lawsuit.
The well-known company Bayer CropScience AG 
(“Bayer”) owns a European patent entitled “aryl urea 
compounds, a method of preparing them, and their 
use as herbicides and growth regulators”. This patent 
covers inter alia a chemical compound called “iodo-
sulfuron”, which acts as a herbicidal substance. On 13 
December 1998 an application to the German com-
petent authority to have this substance included in 
Annex I to Directive 91/414 was filed by a company 
whose rights were afterwards transferred to Bayer. 
On 9 March 2000 the German authority granted said 
company a provisional marketing authorization for a 
herbicide based on “iodosulfuron” and commercially 
4 Article 4(1)(b) Directive 91/414. Moreover, according to Article 
4(1)(c)-(f), plant protection products will not be authorized unless: 
“[...] (c) the nature and quantity of its active substances and, where 
appropriate, any toxicologically or ecotoxicologically significant 
impurities and co-formulants can be determined by appropriate 
methods [...]; (d) its residues, resulting from authorised uses, and 
which are of toxicological or environmental significance, can be 
determined by appropriate methods in general use; (e) its physi-
cal and chemical properties have been determined and deemed 
acceptable for the purposes of the appropriate use and storage of 
the product; (f) where appropriate, the MRLs [maximum residue 
levels] for the agricultural products affected by the use referred to 
in the authorisation have been set or modified in accordance with 
Regulation (EC) No 396/2005”. Authorizations of products contain-
ing active substances are within the competence of EU Member 
States.
5 A term of protection of 20 years is required by Article 33 TRIPS 
Agreement.
6 Regulation (EC) No 1610/96 of the European Parliament and of the 
Council of 23 July 1996 concerning the creation of a supplemen-
tary protection certificate for plant protection products (OJ 1996 
L 198, p. 30) (“Regulation 1610/96”). Recital 5 Regulation 1610/96 
clearly explains the needs for SPCs: “[...] at the moment, the period 
that elapses between the filing of an application for a patent for a 
new plant protection product and authorization to place the said 
plant protection product on the market makes the period of effec-
tive protection under the patent insufficient to cover the invest-
ment put into the research and to generate the resources needed 
to maintain a high level of research”. For an analysis of Regula-
tion 1610/96 see Alice de Pastors, “Plant Protection product sup-
plementary protection certificates”, 11 World Patent Information 
(2000), pp. 59–61.
7 Regulation (EC) No 1768/92 of 18 June 1992 concerning the crea-
tion of a supplementary protection certificate for medicinal prod-
ucts (OJ L 182, 2.7.1992, pp. 1–5).
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known as “Husar”. Indeed, Member States are able 
to issue provisional authorizations relying on Article 
8(1) Directive 91/114. The rationale of this transition-
al measure is the following: as the procedure for the 
inclusion of an active substance in Annex I may take 
several years, a provisional marketing authorization 
is needed in order to enable a gradual assessment of 
properties of new active substances and to make new 
preparations available for use in agriculture8. On 17 
July 2003 the German Federal Court for Patents (Bun-
despatentgericht) granted Bayer a supplementary pro-
tection certificate for “iodosulfuron and its C1 to C12 
alykl esters and salts including iodosulfuron-methyl-
sodium salt”. The calculation of the SPC’s duration 
was carried out taking into account the issue date of 
the provisional authorization, which was effectively 
the first marketing approval related to the product 
in question.
A third party, namely the law firm Hogan Lovells 
International LLP, took legal action against Bayer, 
claiming that the SPC in question was invalid on 
the ground that it had not been issued in conformity 
with the above-mentioned Article 3(1)(b) Regulation 
1610/969. Bayer argued that this provision allows the 
granting of SPCs only after a definitive (not provi-
sional) authorization has been issued.
The Bundespatentgericht thus stayed the proceed-
ings and referred the case to the ECJ, which was es-
sentially asked whether SPCs could also be issued 
on the basis of provisional authorizations granted 
pursuant to Article 8(1) Directive 91/114.
III. The ECJ’s decision
The ECJ’s decision was straightforward. Departing 
from the opinion of the Advocate General, the Court 
held that SPCs for patented plant protection products 
may also be based on provisional marketing authori-
zations.
The ECJ first recognized that Article 3(1)(b) Regu-
lation 1610/96 makes reference only to the admin-
istrative authorization issued pursuant to Article 4 
Directive 91/414 (i.e. the definitive approval); and that 
the wording of this provision might lead to the a con-
trario finding that SPCs cannot be available for plant 
protection products authorized on a provisional basis 
pursuant to Article 8(1) of said directive, as such a 
possibility has not been expressly envisaged10.
Yet, the ECJ noted, the above Article 3(1)(b) should 
not be interpreted exclusively on the basis of its word-
ing, but also taking into account “the overall scheme 
and objectives of the system of which it is a part”11 
(“purposive” interpretation). Indeed the ECJ stressed 
that provisional administrative authorizations grant-
ed for plant protection products containing new ac-
tive substances satisfy the same scientific conditions 
as to reliability as definitive marketing authoriza-
tions: i.e. the requirements that in light of current 
scientific and technical knowledge the products in 
question be effective and safe12. Indeed, Article 8(1)
(b) Directive 91/414 requires the Member State that 
grants a provisional authorization to establish that 
the active substance and the relevant product meet 
the requirements of the above mentioned Articles 
5(1) and 4(1)(b)-(f) of the same directive13.
It is on the basis of such “functional equivalence” 
existing between the conditions required for de-
finitive and provisional authorizations that the ECJ 
found that Article 3(1)(b) Regulation 1610/96 must 
be interpreted in such a manner to also allow the 
granting of SPCs issued on the basis of provisional 
authorizations14.
This finding – the ECJ stressed – is buttressed by 
other provisions of Regulation 1610/96. First, from a 
combined reading of several provisions of Regulation 
1610/9615 it is clear that SPCs are issued with due ac-
count taken of the first administrative approval: and 
the provisional authorization under Article 8(1) Di-
rective 91/414 is undoubtedly the first administrative 
approval granted to the products in question. Moreo-
ver, Article 13(3) Regulation 1610/96 states that, for 
the purposes of calculating the duration of SPCs, pro-
visional first marketing authorizations will be taken 
into account only if they are directly followed by a 
definitive authorization related to the same product. 
As the Court put it, this provision means that SPCs 
can also be issued with reference to products which 
have only obtained provisional authorization.
8 See also the opinion of Advocate General Verica Trstenjak of 17 
June 2010, paras. 46–47. The provisional approval is valid for a 
period not exceeding three years.
9 Indeed, Article 15(1)(a) Regulation 1610/96 provides that SPCs are 
invalid if they are granted contrary to the provisions of Article 3.
10 Para. 31 ECJ’s decision.
11 Para. 32 ECJ’s decision.
12 See also para. 44 ECJ’s decision.
13 See supra notes 3 and 4.
14 Para. 46 ECJ’s decision.
15 Paras. 47 et sqq. ECJ’s decision.
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Thus, according to the ECJ, a “systematic” interpre-
tation of Regulation 1610/96 also supports the above 
finding.
IV. Concluding remarks
The ECJ’s finding that Article 3(1)(b) should be in-
terpreted as allowing the granting of SPCs on the 
basis of provisional authorizations might give rise 
to criticism. One possible criticism could target the 
alleged reduced reliability of provisional approvals, 
given that these authorizations are speedily granted. 
Even the ECJ admitted that the assessment made by 
a EU country when dealing with an application for a 
provisional authorization is by nature “prospective”, 
and necessarily entails a greater margin of uncertain-
ty than would be the case for an assessment carried 
out for definitive marketing authorizations16.
Yet, as we have seen, the Court found that the two 
procedures, provisional and definitive, must be con-
sidered “functionally equivalent” and thus conform-
ing to the general aim of the authorization procedure, 
i.e. ensuring a high standard of protection against the 
risks to human and animal health, groundwater and 
the environment, inter alia.
What should be carefully pondered are the con-
sequences for owners of SPCs if a definitive market-
ing authorization is not granted even following the 
issue of a provisional approval. There is no doubt 
that under these circumstances the SPC would ex-
pire17. However, this outcome would produce legal 
and economic uncertainties, to the detriment of (for-
mer) SPCs owners. Indeed, how could a company ad-
equately prepare its strategic investments, if it feared 
that its SPC – based on a mere provisional authoriza-
tion – might expire as a consequence of a more thor-
ough examination of its plant protection product?
The “functional equivalence” argument is not the 
only factor taken into account by the Court. The ECJ’s 
decision also seems to have been prompted by the 
general and accepted practice of most EU Member 
States, including Germany, Belgium, Italy, Spain, 
UK, France, Austria, the Netherlands and Ireland. In 
these countries SPCs for plant protection products 
are usually granted on the basis of provisional ap-
provals issued under Article 8(1) Directive 91/414. 
Generally speaking, it seems that in the EU 90 % 
of the SPCs issued in relation to these products are 
based on provisional authorizations18.
Bearing this widely accepted practice in mind, it is 
easy to understand why the ECJ has not interpreted 
Article 3(1)(b) Regulation 1610/96 as prohibiting the 
issue of SPCs on the basis of provisional authoriza-
tions only. Indeed, any such interpretation would 
have had dangerous spill-over effects, i.e. beyond the 
specific issue of the invalidity of the SPC in Lovells 
v. Bayer. For example, most SPCs in the EU – having 
been granted on the basis of provisional approvals – 
could have been invalidated upon the request of any-
one: and this would have entailed serious economic 
consequences for the plant protection industry that 
relies so heavily on patent protection and particularly 
on SPCs.
16 Para. 45 ECJ’s decision.
17 See also Article 14 Regulation 1610/96.
18 See the position paper by the European Crop Protection Associa-
tion of 28 September 2009, quoted in the opinion of Advocate 
General Verica Trstenjak, para. 84.
